R. Molife

918 total citations
24 papers, 694 citations indexed

About

R. Molife is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Molife has authored 24 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Molife's work include Cancer Treatment and Pharmacology (6 papers), Prostate Cancer Treatment and Research (6 papers) and Histone Deacetylase Inhibitors Research (4 papers). R. Molife is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Prostate Cancer Treatment and Research (6 papers) and Histone Deacetylase Inhibitors Research (4 papers). R. Molife collaborates with scholars based in United Kingdom, United States and France. R. Molife's co-authors include Johann S. de Bono, Barry W. Hancock, Gerhardt Attard, Chris Parker, Paul Lorigan, Debashis Sarker, Peter C.C. Fong, David P. Dearnaley, David Olmos and C. P. Carden and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

R. Molife

23 papers receiving 683 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Molife United Kingdom	11	300	291	277	162	70	24	694
Andreas Varkaris United States	17	393 1.3×	331 1.1×	327 1.2×	253 1.6×	49 0.7×	46	836
Hideaki Mitsui Japan	18	393 1.3×	320 1.1×	290 1.0×	206 1.3×	42 0.6×	47	863
Hidetoshi Ehara Japan	14	444 1.5×	153 0.5×	326 1.2×	247 1.5×	51 0.7×	50	856
Sharon Glaysher United Kingdom	16	324 1.1×	286 1.0×	143 0.5×	112 0.7×	27 0.4×	30	690
A. Delacruz United States	13	322 1.1×	351 1.2×	438 1.6×	106 0.7×	59 0.8×	30	900
Isabelle Valo France	16	311 1.0×	381 1.3×	462 1.7×	211 1.3×	33 0.5×	34	1.0k
David Molkentine United States	16	371 1.2×	357 1.2×	186 0.7×	125 0.8×	40 0.6×	30	708
Mareyuki Endoh Japan	18	306 1.0×	187 0.6×	195 0.7×	158 1.0×	80 1.1×	33	786
U. Ramp Germany	15	435 1.4×	175 0.6×	166 0.6×	143 0.9×	33 0.5×	35	629
Lorenza Pistola Italy	17	472 1.6×	502 1.7×	414 1.5×	281 1.7×	20 0.3×	38	982

Countries citing papers authored by R. Molife

Since Specialization

Citations

This map shows the geographic impact of R. Molife's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Molife with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Molife more than expected).

Fields of papers citing papers by R. Molife

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Molife. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Molife. The network helps show where R. Molife may publish in the future.

Co-authorship network of co-authors of R. Molife

This figure shows the co-authorship network connecting the top 25 collaborators of R. Molife. A scholar is included among the top collaborators of R. Molife based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Molife. R. Molife is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lopez, Juanita, Julia Lai‐Kwon, R. Molife, et al.. (2023). A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. British Journal of Cancer. 129(5). 811–818. 10 indexed citations

Loriot, Yohann, Karim Fizazi, Robert J. Jones, et al.. (2014). Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs. 32(5). 995–1004. 54 indexed citations

Olmos, David, M. Puglisi, Leonardo Trani, et al.. (2010). An analysis of the risk of toxicity associated with participation in phase 1 oncology trials of novel molecularly targeted agents (mta) at the drug development unit, royal marsden hospital. Annals of Oncology. 21. 168–168. 5 indexed citations

Steele, Nicola, Jane A. Plumb, Laura Vidal, et al.. (2010). Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemotherapy and Pharmacology. 67(6). 1273–1279. 45 indexed citations

Olmos, David, Hendrik‐Tobias Arkenau, Joo Ern Ang, et al.. (2008). Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Annals of Oncology. 20(1). 27–33. 194 indexed citations

Sarker, Debashis, R. Molife, T. R. J. Evans, et al.. (2008). A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(7). 2075–2081. 117 indexed citations

Molife, R., James Lee, Daniel Petrylak, et al.. (2007). A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 2 indexed citations

Attard, Gerhardt, Alison Reid, Rajesh Kumar Sinha, et al.. (2007). Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC). Molecular Cancer Therapeutics. 6. 1 indexed citations

Olmos, David, R. Molife, Scott H. Okuno, et al.. (2007). Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors.. Molecular Cancer Therapeutics. 6. 7 indexed citations

10.

Molife, R., Thomas H. Cartwright, David Loesch, et al.. (2007). Phase II multicenter, two-stage study of E7389 in patients with hormone refractory prostate cancer with advanced and/or metastatic disease stratified by prior chemotherapy. Journal of Clinical Oncology. 25(18_suppl). 15513–15513. 5 indexed citations

11.

Legge, Francesco, David Eaton, R. Molife, et al.. (2006). Participation of patients with gynecological cancer in phase I clinical trials: Two years experience in a major cancer center. Gynecologic Oncology. 104(3). 551–556. 9 indexed citations

12.

Greystoke, Alastair, Sarah P. Blagden, Anne Thomas, et al.. (2006). A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Annals of Oncology. 17(8). 1313–1319. 19 indexed citations

13.

Attard, Gerhardt, Debashis Sarker, Alison Reid, et al.. (2006). Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. British Journal of Cancer. 95(7). 767–774. 56 indexed citations

14.

Sarker, Debashis, Jonathan J. Evans, R. Molife, et al.. (2006). A phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of CHIR-258, a novel oral multiple receptor tyrosine kinase (RTK) inhibitor. Journal of Clinical Oncology. 24(18_suppl). 3043–3043. 2 indexed citations

15.

Molife, R., Stephen G. Patterson, Charles E. Riggs, et al.. (2006). Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 24(18_suppl). 14554–14554. 7 indexed citations

16.

Blagden, Sarah P., R. Molife, Miranda Payne, et al.. (2005). Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors.. Clinical Cancer Research. 11. 1 indexed citations

17.

Zekri, Jamal, Rachael Hough, J. M. Davies, et al.. (2003). Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. British Journal of Cancer. 88(9). 1335–1338. 7 indexed citations

18.

Molife, R. & Barry W. Hancock. (2002). Adjuvant therapy of malignant melanoma. Critical Reviews in Oncology/Hematology. 44(1). 81–102. 50 indexed citations

19.

Molife, R., et al.. (2001). Gender and survival in malignant tumours. Cancer Treatment Reviews. 27(4). 201–209. 47 indexed citations

20.

Neil, Sheila Mac, Paula C. Eves, R. Molife, et al.. (2000). Oestrogenic Steroids and Melanoma Cell Interaction with Adjacent Skin Cells Influence Invasion of Melanoma Cells In Vitro. Pigment Cell Research. 13(s8). 68–72. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact